MX2024012195A - Formas amorfas y cristalinas de los antagonistas de mci-1 - Google Patents

Formas amorfas y cristalinas de los antagonistas de mci-1

Info

Publication number
MX2024012195A
MX2024012195A MX2024012195A MX2024012195A MX2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A
Authority
MX
Mexico
Prior art keywords
amorphous
antagorists
mci
crystalline
crystalline forms
Prior art date
Application number
MX2024012195A
Other languages
English (en)
Spanish (es)
Inventor
Yosup Rew
Van Luu
Manuel Zancanella
Mary Chaves
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024012195A publication Critical patent/MX2024012195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2024012195A 2022-04-05 2024-10-02 Formas amorfas y cristalinas de los antagonistas de mci-1 MX2024012195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263327656P 2022-04-05 2022-04-05
PCT/US2023/017505 WO2023196361A1 (en) 2022-04-05 2023-04-05 Amorphous and crystalline forms of mci-1 antagonists

Publications (1)

Publication Number Publication Date
MX2024012195A true MX2024012195A (es) 2024-11-08

Family

ID=86386948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012195A MX2024012195A (es) 2022-04-05 2024-10-02 Formas amorfas y cristalinas de los antagonistas de mci-1

Country Status (9)

Country Link
US (1) US20240140966A1 (cg-RX-API-DMAC10.html)
EP (1) EP4504738A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025511331A (cg-RX-API-DMAC10.html)
AU (1) AU2023250874A1 (cg-RX-API-DMAC10.html)
CA (1) CA3255077A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024012195A (cg-RX-API-DMAC10.html)
TW (1) TW202404982A (cg-RX-API-DMAC10.html)
UY (1) UY40218A (cg-RX-API-DMAC10.html)
WO (1) WO2023196361A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255998A (zh) 2022-05-04 2025-01-03 吉利德科学公司 特定mcl-1抑制剂的盐和多晶型物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
KR20230113577A (ko) * 2020-11-25 2023-07-31 암젠 인크 알데히드의 거울상이성질체 선택적 알케닐화

Also Published As

Publication number Publication date
AU2023250874A1 (en) 2024-10-10
WO2023196361A1 (en) 2023-10-12
EP4504738A1 (en) 2025-02-12
US20240140966A1 (en) 2024-05-02
JP2025511331A (ja) 2025-04-15
TW202404982A (zh) 2024-02-01
CA3255077A1 (en) 2023-10-12
UY40218A (es) 2023-10-13

Similar Documents

Publication Publication Date Title
DOP2021000234A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina
CO2024013985A2 (es) Moduladores del transductor de señal y activador de la transcripción (stat) y usos de los mismos
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
MX2024008616A (es) Moduladores stat y usos de los mismos
PE20240493A1 (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
DOP2024000231A (es) Compuestos y usos de estos
MX2020011639A (es) Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CO2024012423A2 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
UY39517A (es) Inhibidores de la btk
CO5200848A1 (es) Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales
UY28695A1 (es) Derivados de difenilazetidona
CY1109891T1 (el) Παραγωγα ν-(αρυλαλκυλ)-1η-πυρρολοπυριδιν-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες
CL2020002663A1 (es) Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
AR114239A1 (es) Oxadiazoles
CL2021000086A1 (es) Derivados de pirrolo [1,2-b] piridazina
UY40218A (es) Formas amorfas y cristalinas de los antagonistas de mci-1
PE20230323A1 (es) Compuestos de azalactama como inhibidores de hpk1
UY27338A1 (es) Nuevos derivados de ácido sulfónico
PE20230853A1 (es) Procesos para elaborar compuestos serd triciclicos que tienen un resto sustituido de fenilo o piridinilo
AR043673A1 (es) Compuestos heterociclicos inhibidores no nucleosidos de la transcriptasa inversa i, preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del sida
UY40217A (es) Formas de sal y solvatos de antagonistas de mci-1
ES2614781T3 (es) Naftopiranos anillados fotocrómicos compatibles con endurecimiento por rayos UV
CL2023002064A1 (es) Derivados de ácido urólico sintético y métodos de uso de estos